Hold Sun Pharmaceutical Industries Target Of Rs 460: Sharekhan

Sun Pharma’s Q2FY2020 results are in line with estimates. Staggered penetration of specialty portfolio, higher specialty promotional spends, increasing R&D, and continued pricing issues in the U.S. are likely to be the key challenge for earnings growth We expect the company to report sales and profit CAGR of 14% and 22%, respectively, over the next two years. – Money Control

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.